All company sites gemabank.ru celltranspl.ru reprobank.ru genetico.ru stem-cells.ru sprs-therapy.ru celltech.ru neovasculgen.ru Russian English About company Press Center Directions Products Investors 24.09 Forum "BioKirov 2015": the future belongs to biotechnology On September 17-18, the III International Forum "BioKirov 2015" was held in Kirov. The forum was devoted to the development of biotech in the Russian Federation, the discussion was held in 9 thematic sections. 14.09 The results of HSCI's scientific work were included in the TOP 25 poster reports at the International Congress on Regenerative Medicine Scientists from the Human Stem Cell Institute (HSCI) presented the results of their work in Boston at the TERMIS-2015 World Congress. All news Human Stem Cell Institute (PJSC "HSCI") The Human Stem Cell Institute (HSCI PJSC) is a Russian public biotechnology company founded in 2003. HSCI's areas of activity are development, commercialization, and further promotion on the market of its own innovative medicines and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. The company aims to create a new culture of medical care for a person - the development of healthcare in the field of personalized and preventive medicine. HSCI owns the largest bank in the country of the personal storage of umbilical cord blood stem cells - Gemabank ® , as well as a bank of human reproductive cells - Reprobank ® (private storage and donation). The company brought to the market the first Russian gene therapy drug for the treatment of lower limb ischemia of atherosclerotic genesis - Neovasculgen ® , as well as an innovative medical technology for the use of dermal autofibroblasts to restore skin with signs of age and other structural changes - SPRS-therapy ® . ИСКЧ реализует социально-значимый проект Genetico по развитию лаборатории новых методов генетической диагностики, а также общероссийской сети медико-генетических центров для предоставления услуг генетической диагностики и консультирования с целью раннего выявления и профилактики наследственных заболеваний, а также патологий с генетической составляющей (включая услуги ДНК-скрининг, ПГД, Prenetix®, а также сервисы в области онкогенетики и биоинформатики). С 2013 года спектр услуг генетической диагностики и консультирования предоставляется на базе нового лабораторно-производственного комплекса, созданного ИСКЧ в Москве. Компания нацелена на развитие своих продуктов на российском и мировом рынках. PJSC HSCI is the issuer of the RII sector of the Moscow Exchange (ticker: ISKJ ). HSCI's initial public offering in December 2009 was the first IPO of a biotech company in Russia. Disclaimer List of insider information © 2003-2015 Human Stem Cell Institute